Evidence map›Paper›PMID 29580953›Full record

ArticleNeuropharmacology2018

Effects of drugs of abuse on channelrhodopsin-2 function.

Dominic A Gioia, Minfu Xu, Wesley N Wayman, John J Woodward

Abstract read
In one paragraph

Article in Neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. New era of optogenetics: from the central to peripheral nervous system.Critical reviews in biochemistry and molecular biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dominic A GioiaMedical University of South Carolina, Institute of Psychiatry, 67 President St, Charleston, SC, 29425, United States. Electronic address: gioia@musc.edu.
Minfu XuMedical University of South Carolina, Institute of Psychiatry, 67 President St, Charleston, SC, 29425, United States. Electronic address: xum@musc.edu.
Wesley N WaymanMedical University of South Carolina, Institute of Psychiatry, 67 President St, Charleston, SC, 29425, United States. Electronic address: waymanw@musc.edu.
John J WoodwardMedical University of South Carolina, Institute of Psychiatry, 67 President St, Charleston, SC, 29425, United States. Electronic address: woodward@musc.edu.

Funding

TREATING ETHANOL WITHDRAWAL WITH LORAZEPAM/NALTREXONEP50AA010761 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HOWARD C. BECKER · 1996 to 2026
$46.8M
TRAINING IN ALCOHOL TREATMENT RESEARCHT32AA007474 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI John J. Woodward · 1987 to 2026
$8.5M
Neural Actions of TolueneR01DA013951 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WOODWARD, JOHN J. · 2002 to 2023
$6.4M
Ethanol Sensitivity of Native and Cloned NMDA ReceptorsR37AA009986 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WOODWARD, JOHN J. · 2009 to 2018
$3.8M
NIAAA NIH HHS P50 AA010761NIAAA NIH HHS R37 AA009986NIAAA NIH HHS T32 AA007474NIDA NIH HHS R01 DA013951
6 · The paper itself

Abstract

Channelrhodopsins are light activated ion channels used extensively over the past decade to probe the function of genetically defined neuronal populations and distinct neural circuits with high temporal and spatial precision. The widely used Channelrhodopsin-2 variant (ChR2) is an excitatory opsin that undergoes conformational changes in response to blue light, allowing non-selective passage of protons and cations across the plasma membrane thus leading to depolarization. In the addiction neuroscience field, opsins such as ChR2 provide a means to disambiguate the overlapping circuitry involved in mediating the reinforcing and aversive effects of drugs of abuse as well as to determine the plasticity that can occur in these circuits during the development of dependence. Although ChR2 has been widely used in animal models of drug and alcohol self-administration, direct effects of drugs of abuse on ChR2 function may confound its use and lead to misinterpretation of data. As a variety of neuronal ion channels are primary targets of various drugs of abuse, it is critical to determine whether ChR2-mediated currents are modulated by these drugs. In this study, we performed whole-cell electrophysiological recordings in HEK293 cells expressing the commonly used ChR2(H134R) variant and examined the effects of various drugs of abuse and other commonly used agents on light-induced currents. We found no differences in ChR2-mediated currents in the presence of 30 μM nicotine, 30 μM cocaine, 100 μM methamphetamine or 3 mM toluene. Similarly, ChR2 currents were insensitive to 30 mM ethanol but higher concentrations (100-300 mM) produced significant effects on the desensitization and amplitude of light-evoked currents. Tetrahydrocannabinol (1-10 μM) and morphine (30-100 μM) significantly inhibited ChR2 currents while the cannabinoid receptor antagonist AM-251 had no effect. The sodium channel blocker tetrodotoxin (5 μM) and the generic channel blocker/contrast agent gadolinium chloride (10 mM) also reduced ChR2 currents while the divalent ion magnesium (10 mM) had no effect. Together, the results from this study highlight the importance of conducting appropriate control experiments when testing new compounds in combination with optogenetic approaches.

Indexed as

CationsChannelrhodopsinsCocaineDose-Response Relationship, DrugDronabinolEthanolGadoliniumHEK293 CellsHumansIllicit DrugsMagnesiumMembrane PotentialsMembrane Transport ModulatorsMethamphetamineMorphineNicotineCationsChannelrhodopsinsCocaineDronabinolEthanolGadoliniumIllicit DrugsMagnesiumMembrane Transport ModulatorsMethamphetamineMorphineNicotineTetrodotoxinTolueneChannelrhodopsinLight-activated channelOptogeneticsSubstance abuse

Identifiers

PMID29580953
PMCPMC5975088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.